

# Burden of COVID-19: a preliminary analysis in the population of Saudi Arabia

Syed Mohammed Basheeruddin Asdaq<sup>Corresp., 1</sup>, Syed Imam Rabbani<sup>2</sup>, Mohammed Kanan Alshammari<sup>3</sup>, Reem Saud Alshammari<sup>4</sup>, Mehnaz Kamal<sup>5</sup>, Mohd. Imran<sup>6</sup>, Noufah Aqeel AlShammari<sup>7</sup>, May Faiz Al Twallah<sup>8</sup>, Abdulmjeed hussain alshahrani<sup>7</sup>

<sup>1</sup> Pharmacy Practice, Almaarefa University, RIYADH, Riyadh, Saudi Arabia

<sup>2</sup> Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia

<sup>3</sup> Department of Pharmaceutical Care,, Rafha Central Hospital, Rafha, Saudi Arabia

<sup>4</sup> Department of Pharmaceutical Care, Maternity and Children Hospital, Rafha, Saudi Arabia

<sup>5</sup> Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia

<sup>6</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern border University, Rafha, Saudi Arabia

<sup>7</sup> Security Forces Hospital, RIYADH, Riyadh, Saudi Arabia

<sup>8</sup> Northern Area Armed Forces hospital, Hafar albaten, Saudi Arabia

Corresponding Author: Syed Mohammed Basheeruddin Asdaq  
Email address: sasdag@mcst.edu.sa

**Background** Coronavirus infection (COVID-19) has resulted in an unprecedented number of human deaths and economic losses. Analyzing the role of disease in different groups of people is useful for determining the burden of disease. As a result, the purpose of this study was to investigate the influence of COVID-19 on the Saudi Arabian population's quality of life, with a particular emphasis on the likely fall in their life expectancy.

**Methods** A cross-sectional and retrospective analysis of 2988 patients was performed to assess COVID-19-induced mortality and complications in the community. The data was gathered from official websites that track the disease's impact daily. On the acquired data, disability-adjusted life years (DALYs) and relative risk analysis were performed. The data was statistically analyzed using SPSS IBM 25. The Pearson's correlation test was used to examine the relationship between age and disease impact. The significance of the findings was determined by using a P value of less than 0.05. **Results** The data from the study indicated that the positive test rate, infection rate, and mortality rate in the population were 1.84%, 1.54%, and 1.59%, respectively. The highest mortality was observed in Riyadh (17%), followed by Jeddah (8.7%) and Makkah (7.5%). The DALYs/1,00,000 inhabitants increased progressively as the age of the population increased, and the highest value was found for those over 70 years old (25.73). Similarly, the risk outcome (55%) increased significantly ( $p = 0.037$ ) from 40 years onwards, and the maximum was observed at above 70 years (184%). The correlation analysis indicated a significant association ( $p = 0.032$ ) between age and COVID-19 induced mortality from the 40-year-old

population onwards. **Conclusion** The current study found that the COVID-19 load in Saudi Arabia was comparable to that in nations that were said to have performed well during the pandemic. DALYs increased from 40 years to 60 years, although people over 60 years had a lower life expectancy and were more susceptible to infection. After 60 years, the occurrence of numerous co-morbid illnesses may have added to the population's burden of COVID-19. Further research in this area may yield a more precise estimate of the COVID-19-induced burden on the entire population.

1 **Burden of COVID-19: a preliminary analysis in the population of Saudi Arabia**

2

3 **Syed Mohammed Basheeruddin Asdaq<sup>1\*</sup>, Syed Imam Rabbani<sup>2</sup>, Mohammed Kanan**  
4 **Alshammari<sup>3</sup>, Reem Saud Alshammari<sup>4</sup>, Mehnaz Kamal<sup>5</sup>, Mohd. Imran<sup>6</sup>, Noufah Aqeel**  
5 **AlShammari<sup>7</sup>, May Faiz Al Twallah<sup>8</sup>, Abdulmjeed hussain alshahrani<sup>9</sup>**

6

7 <sup>1\*</sup>Department of Pharmacy Practice, College of Pharmacy, Almaarefa University, Dariyah,  
8 13713, Riyadh, Saudi Arabia, [sasdaq@gmail.com](mailto:sasdaq@gmail.com)

9 <sup>2</sup>Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University,  
10 Buraydah 51452, Kingdom of Saudi Arabia, [syedrabbani09@yahoo.com](mailto:syedrabbani09@yahoo.com) (S.I.R.)

11 <sup>3</sup>Department of Pharmaceutical Care, Rafha Central Hospital, North Zone, Rafha, 91911, Saudi  
12 Arabia. ([ii\\_kanan101@outlook.com](mailto:ii_kanan101@outlook.com))

13 <sup>4</sup>Department of Pharmaceutical Care, Maternity and Children Hospital, Rafha 91911, Saudi  
14 Arabia. ([ph.reemy20@gmail.com](mailto:ph.reemy20@gmail.com))

15 <sup>5</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz  
16 University, Al-Kharj 11942, Saudi Arabia. ([mailtomehnaz@gmail.com](mailto:mailtomehnaz@gmail.com))

17 <sup>6</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University,  
18 Rafha 91911, Saudi Arabia. ([imran.pchem@gmail.com](mailto:imran.pchem@gmail.com))

19 <sup>7</sup>Department of Pharmaceutical Care, Security Forces Hospital, Riyadh 12211, Saudi Arabia.  
20 ([Ph.nofa1992@gmail.com](mailto:Ph.nofa1992@gmail.com))

21 <sup>8</sup>Department of Pharmaceutical Care, Northern Area Armed Forces hospital , Hafar albaten  
22 10018, Saudi Arabia. ([May-11@windowslive.com](mailto:May-11@windowslive.com))

23 <sup>9</sup>Department of Pharmaceutical Care, Security Forces Hospital, Riyadh 12211, Saudi Arabia.  
24 ([alshaahraanii@gmail.com](mailto:alshaahraanii@gmail.com))

25

26 Corresponding Author:

27 **Prof. Dr. Syed Mohammed Basheeruddin Asdaq,**  
28 Department of Pharmacy Practice,  
29 College of Pharmacy,  
30 Almaarefa University, Dariyah, 13713, Riyadh, Saudi Arabia,  
31 [sasdag@mest.edu.sa](mailto:sasdag@mest.edu.sa)/[sasdaq@gmail.com](mailto:sasdaq@gmail.com)

32

33

34

**35 ABSTRACT****36 Background**

37 Coronavirus infection (COVID-19) has resulted in an unprecedented number of human deaths and  
38 economic losses. Analyzing the role of disease in different groups of people is useful for  
39 determining the burden of disease. As a result, the purpose of this study was to investigate the  
40 influence of COVID-19 on the Saudi Arabian population's quality of life, with a particular  
41 emphasis on the likely fall in their life expectancy.

42

**43 Methods**

44 A cross-sectional and retrospective analysis of 2988 patients was performed to assess COVID-19-  
45 induced mortality and complications in the community. The data was gathered from official  
46 websites that track the disease's impact daily. On the acquired data, disability-adjusted life years  
47 (DALYs) and relative risk analysis were performed. The data was statistically analyzed using  
48 SPSS IBM 25. The Pearson's correlation test was used to examine the relationship between age  
49 and disease impact. The significance of the findings was determined by using a P value of less  
50 than 0.05.

51

**52 Results**

53 The data from the study indicated that the positive test rate, infection rate, and mortality rate in the  
54 population were 1.84%, 1.54%, and 1.59%, respectively. The highest mortality was observed in  
55 Riyadh (17%), followed by Jeddah (8.7%) and Makkah (7.5%). The DALYs/1,00,000 inhabitants  
56 increased progressively as the age of the population increased, and the highest value was found for  
57 those over 70 years old (25.73). Similarly, the risk outcome (55%) increased significantly ( $p =$   
58 0.037) from 40 years onwards, and the maximum was observed at above 70 years (184%). The  
59 correlation analysis indicated a significant association ( $p = 0.032$ ) between age and COVID-19  
60 induced mortality from the 40-year-old population onwards.

61

**62 Conclusion**

63 The current study found that the COVID-19 load in Saudi Arabia was comparable to that in nations  
64 that were said to have performed well during the pandemic. DALYs increased from 40 years to 60

65 years, although people over 60 years had a lower life expectancy and were more susceptible to  
66 infection. After 60 years, the occurrence of numerous co-morbid illnesses may have added to the  
67 population's burden of COVID-19. Further research in this area may yield a more precise estimate  
68 of the COVID-19-induced burden on the entire population.

69 **Keywords** – COVID-19, Mortality, DALYs, Relative Risk, Burden, Saudi Arabia.

70

## 71 **1. INTRODUCTION**

72 Saudi Arabia is one of the seven countries that make up the Gulf Cooperative Council (GCC)  
73 group of nations. The country is the largest both in terms of geography and population and is  
74 located between the Persian Gulf and the Red Sea (Alahmadi and Atkinson, 2019). Human  
75 habitats are distributed throughout the country but mostly concentrated in cities and towns such  
76 as Riyadh, Damman, Makkah, Taif, Jeddeh, and Madinah. Although the population in these  
77 places includes mostly Saudi citizens, people from other nationalities who form the workforce  
78 can also be found in a significant number (Asharaf and Alshekteria, 2008).

79 In March 2020, the first case of coronavirus infection (COVID-19) was reported in Saudi  
80 Arabia's eastern region. Since then, the country has seen an outbreak of infection that has spread  
81 to every nook and corner (Al-Tawfiq and Memish, 2020). According to official data, the country  
82 was infected with COVID-19 in two waves.

83 (<https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/covid19.aspx>. The first  
84 wave began in March 2020 and lasted until December 2020, while the second wave began in  
85 January 2021 and has been slow since August 2021. The healthcare authorities took several  
86 proactive measures to prevent the spread of infection, and some of them included international  
87 travel bans, restrictions on social gatherings, compulsory wearing of facemasks, and maintaining  
88 social distance in public places (Al-Tawfiq and Memish, 2020). These preventive measures were  
89 considered the most stringent among the region's nations, and they were largely linked to a  
90 decrease in COVID-19 positive cases and population mortality.

91 The COVID-19 pandemic has caused devastating effects not only on human health but also on  
92 the economy. Several people lost their livelihoods, in addition to their dear and near ones.

93 According to a report, the unemployment rate during the pandemic peaked in several parts of the  
94 world (Deb et al., 2020). Big business establishments closed during this period, causing  
95 irreparable damage to the GDP (gross domestic product). Previous studies have indicated that the

96 rapid spread of COVID-19, its mortality, and complications have caused an enormous burden on  
97 mankind (Bonaccorsi et al., 2020).

98 The available data suggests that COVID-19 can cause infection in all age groups. In most  
99 patients, the infection is reported with mild symptoms such as fever, sore throat, and body aches.  
100 The severity and complications depend on several factors, and important among them are the age  
101 and co-morbid conditions of patients (Zhou, 2020). Estimating the mortality rate, case-fatality  
102 ratio, and crude-fatality rate are reported to provide a direct measure of the impact of a disease  
103 on the population. However, these methods do not determine the loss of life expectancy due to  
104 either mortality or disability (Gaunt et al., 2011). The burden of COVID-19 due to loss of life or  
105 complications has been reported to affect the life expectancy of the population. The global  
106 burden of a disease is an important measure for calculating the loss of quantity and quality of  
107 life. This can be calculated in several ways, the most important being disability-adjusted life  
108 years (DALYs). DALYs measure the number of years of life lost due to a disease or due to its  
109 complications (Nurchis et al., 2020).

110 A study conducted in sixteen European nations indicated a total loss of 4354 DALYs per  
111 1,00,000 habitats. The data suggested that Italy, Sweden, Czechia, and the Netherlands suffered  
112 the maximum loss due to COVID-19, while the least effect was found in Estonia and Finland  
113 (Al-Aly et al., 2021). The DALY data is also reported to indicate the implications of the  
114 prevention or treatment strategies adopted by healthcare providers for a particular disease (Jo et  
115 al., 2020). According to reports, Saudi Arabia is the second most infected country in the Gulf  
116 region with COVID-19 (Alharbi et al., 2021). Since analyzing the infection rate and mortality  
117 might not be sufficient to indicate the burden of COVID-19, this study was planned to evaluate  
118 DALY and relative risk of infection as parameters of the burden of disease in Saudi Arabia.

119

## 120 **2. Materials and methods**

### 121 ***2.1 Study data***

122 The comprehensive data sheets on COVID-19 published on official websites of the ministry of  
123 health such as MOH (<https://www.moh.gov.sa/en/Pages/default.aspx>), COVID-19 Dashboard  
124 (<https://covid19.moh.gov.sa/>) and Waqeya (<https://covid19.cdc.gov.sa/>) were retrieved.

125 Cumulative data on the total number of reverse transcriptase-polymerase chain reaction (RT-

126 PCR) tests conducted, the number of COVID-19 positive cases detected, and mortality due to  
127 infection was recorded in an excel sheet from March 2020, to October, 2021.

128 The general authority of statistics, the ministry of health, and published articles gathered data on  
129 population size, population density, age, and the number of COVID-19 infections (Al-Tawfiq  
130 and Memish, 2020). The Ministry of Health's Health Electronic Surveillance Network (HESN)  
131 was also used to retrieve data from patients treated for COVID-19. This system collected data on  
132 the demographic characteristics of COVID-19 positive patients from various parts of the country.  
133 The burden of disease was calculated using data from 2988 patients gathered from various  
134 sources. The following is the region-wise distribution of COVID-19 positive cases chosen for  
135 this study: Riyadh – 834, Makkah – 502, Jeddah – 439, Madinah – 306, Dammam – 217, Taif –  
136 167, Buraidah – 107, Khobar – 103, Abha – 72, Dahran – 51, and the rest from other parts of the  
137 country.

138

## 139 **2.2 Descriptive analysis**

140 The data collected from the previous mentioned sources was analysed in the following ways:

- 141 • **Positive test rate:** The total number of tests conducted to determine the presence of  
142 COVID-19 in the population and the number of confirmed cases detected were utilized to  
143 find the positive test rate (Rothan and Byrareddy, 2020).
- 144 • **Infection rate:** The total number of confirmed COVID-19 cases detected in the whole  
145 population of the country was represented as the infection rate (Jo et al., 2020).
- 146 • **The mortality rate:** The total number of deaths recorded in the population due to  
147 COVID-19 was calculated from the total number of confirmed COVID-19 cases (Baud et  
148 al., 2020).
- 149 • **Case-fatality ratio (CFR):** This value was calculated using the formula described by  
150 Onder et al., 2020 (Onder et al., 2020).

151 (Total number of deaths multiplied by 100)/Total number of confirmed cases = CFR

- 152 • **DALY analysis:** The DALY was calculated using the method described by Murray and  
153 Lopez in 2020, and it is the sum of years of life lost (YLL) + years lost due to disability  
154 (YLD) (Murray et al., 1994). YLL was calculated from the number of deaths reported for  
155 each age group in the population and the life expectancy lost at the time of death. The  
156 YLD was calculated from the total number of COVID-19 positive cases for each group of

157 the population, multiplied by the loss of expected years due to disability and the disability  
158 weight. The value mentioned for the disability weight due to COVID-19 in the literature  
159 was used for YLD (9). DALY data was represented per 1,00,000 inhabitants according to  
160 the population size of the country as indicated by the general authority of statistics.

161 • **Relative risk (RR) analysis compares the likelihood of mortality for a specific group of**  
162 **people to the risk of death for the entire population (Mathers et al., 2006).** It is  
163 calculated from the formula.

164  $RR = \text{Risk in one group} / \text{Risk in all the other groups.}$

165

### 166 **2.3 Representation of data**

167 The data recorded for the positive test rate, infection rate, and mortality rate was represented as  
168 percentages graphically (Figure-1). Further, the mortality recorded in five major cities in Saudi  
169 Arabia is indicated as a percentage (Figure-2). The data from the DALY analysis was  
170 represented in tabular form (Table-1) as YLL, YLD, DALYs, and DALYs per 1,00,000  
171 inhabitants. The analysis of relative risk was represented as CFR, RR, and risk outcome in  
172 different groups of the population in tabular form (Table-2).

173

### 174 **2.4 Ethical clearance**

175 The data was conducted after obtaining ethical clearance from the research committee of the  
176 College of Pharmacy (MCST/COP #20/2021), AlMaarefa University, Riyadh, Saudi Arabia.

177

### 178 **2.5 Statistical analysis**

179 The data obtained from the study was statistically analyzed by SPSS IBM 25 software. The data  
180 collected from 2988 patients was categorized into different age groups. The sample size in  
181 different age-groups varied between 69 and 441. Due to the requirements of the statistical  
182 software, incomplete data from approximately 107 patients was not considered. In addition, this  
183 number was excluded from the 2988 patient records that were used for the analysis. The data for  
184 each group of patients was entered and analyzed for variables such as years of life lost (YLL),  
185 years lost due to disability (YLD), case fatality ratio (CFR), relative risk, and the outcome of  
186 risk. Both parametric and non-parametric tests were utilized for the statistical analysis. The one-  
187 way analysis of variance (ANOVA) was used to test the hypothesis that population distribution

188 influences disease outcome. In this objective, the influence of the age of the population was  
189 tested over the outcome of COVID-19 and a comparison was drawn between groups. A non-  
190 parametric test such as Mann-Whitney was used to analyze the second objective, that the  
191 outcome of the COVID-19 is independent of the population's distribution. Further, the Pearson  
192 coefficient of correlation was used to determine the association between two variables. While  
193 analyzing the data, a fixed confidence interval (lower – 95% and upper – 95%) was used (Jo et  
194 al., 2020). A *P-value* of less than 0.05 was considered to determine the significance of all the  
195 analysis.

196

197

### 198 3. RESULTS

#### 199 ***3.1 Infection rate and mortality rate due to COVID-19 in Saudi Arabia***

200 Figure 1 represents the values of the positive test rate, infection rate, and mortality rate. A total  
201 of 29,841,399 COVID-19 tests were conducted on the population on October 18, 2021. The total  
202 number of COVID-19 positive cases detected was 5,47,969, and therefore the positive test rate  
203 was found to be 1.836%. Saudi Arabia has a population of 35,498,886 people and the infection  
204 rate in them was found to be 1.54%. The total mortality recorded in the COVID-19 diagnosed  
205 patients was found to be 8,765 and hence the mortality rate was calculated as 1.599%.

206

#### 207 ***3.2 Disability adjusted life years (DALYs) due to COVID-19 in Saudi Arabia***

208 The DALYs calculated by the addition of YLL and YLD indicated the lowest for the 0–9-year  
209 age group. The DALYs per 1,00,000 habitants aged 0 – 9 years old were found to be 0.77. This  
210 value progressively increased to 2.32 in 10– 19 years, 4.05 in 20–29 years, and 7.634 in 30–39  
211 years. From 40–49 years of age, DALYs increased to significant double digits and were found to  
212 be 11.08. For 50–59 years, it was found to be 14.865 and for 60–65 years, it was 21.02. The  
213 highest recorded DALY was observed for people over 70 years old (25.73) (Table-1).

214

#### 215 ***3.3 Relative risk of mortality due to COVID-19 in Saudi Arabia***

216 The relative risk observed in different groups of people is summarized in table 2. The lowest  
217 CFR and negative risk outcome were found in the 0–9-year age group. As the age of the groups  
218 increased, the CFR as well as the RR and risk outcome also increased. A significant level of RR

219 value (1.55,  $P = 0.037$ ) was found for 40–49 years onwards. People of the age group 50–59 years  
220 were found to be at a 78% risk (RR = 1.78,  $P = 0.043$ ), 60 – 69 years old at a 132% risk (RR =  
221 2.32,  $P = 0.008$ ), and the highest risk (184%) was observed in the over 70-year-old population  
222 (RR = 2.84,  $P = 0.006$ ).

223

### 224 ***3.4 Mortality rate recorded in major cities in Saudi Arabia***

225 Figure-2 indicates the five highest mortality rates recorded in the cities of Saudi Arabia. Riyadh,  
226 being the capital city and with the largest population, recorded the highest (17% of total  
227 mortality), followed by Jeddah (8.9%), Makkah (7.5%), Madinah (4.4%), and Dammam (4.3%).  
228 The first two cities are considered the largest in the kingdom in terms of human population and  
229 size.

230

### 231 ***3.5 Summary of correlation between age of population and COVID-19 induced mortality***

232 The association between age of population and the mortality due to COVID-19 indicated lowest  
233 correlation coefficient for 0 – 9 years. The correlation increased to positive level from 10 – 19  
234 years and become significant from 40 – 49 years onwards. The correlation coefficient value for  
235 40 – 49 years old was found to be 0.56 ( $P = 0.032$ ) and it increased to 0.64 in 50 – 59 years old  
236 ( $P = 0.044$ ). The highest correlation value was observed in 60 – 69 years old people ( $r = 0.72$ ,  $P$   
237 = 0.006) and above 70 years ( $r = 0.78$ ,  $P = 0.007$ ) (Table-3).

238

## 239 **4. DISCUSSION**

240 The present study analyzed the burden of COVID-19 in Saudi Arabia. The region recorded a  
241 total of 5,47,969 COVID-19 cases till October 18th, 2021. The first case was detected in a citizen  
242 who came to the country from Persia. Following that, many positive cases were discovered in  
243 various parts of the country, and the infection rate is now considered the second highest after the  
244 United Arab Emirates (Al-Tawfiq and Memish, 2020).

245 The data from the study indicated that the infection rate in the population is 1.54%, although the  
246 health authorities conducted more than 29,841,399 RT-PCR tests (positive test rate is 1.836%)  
247 on the population (Figure-1). The values suggested that the preventive measures imposed by the  
248 healthcare and other government authorities restricted the spread of infection in the population  
249 (Alkhowailed et al., 2020). These values indicated similarities with other countries that were

250 reported to have managed the infection effectively, such as South Korea, Germany, and New  
251 Zealand (Naumann et al., 2020).

252 The World Health Organization (WHO) has recommended several measures to prevent the  
253 spread of the COVID-19 infection ([https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)  
254 [coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)). According to an earlier study, the attitude of the public plays an important  
255 role in achieving the objectives of the healthcare authorities (Al-Zalfawi et al., 2020). The data  
256 suggest that the people of Saudi Arabia responded in a positive manner to the preventive  
257 measures adopted by several authorities during the COVID-19 outbreak.

258 DALY analysis of 2988 patients suggested that YLL (years of life lost) and YLD (years lost due  
259 to disability) due to COVID-19 increased with the age of the population (Table-1). Earlier  
260 studies suggested that YLL and YLD values provide important information not only about the  
261 disease but also the outcome of the treatment strategies against a diseased state (Nurchis et al.,  
262 2020). The progressive increase in DALYs values across age groups suggested a link between  
263 age and COVID-19-related complications (Table 1). A threefold increase in DALY in patients  
264 aged 60–65 years supports previous findings that COVID-19-induced mortality and  
265 complications are common in this age group (Naumann et al., 2020). The data from the present  
266 study also suggested that the mortality rate was high in regions with dense populations (Figure-  
267 2). As reported earlier, urbanization and advancing age carry the burden of several co-  
268 morbidities (Al-Zalfawi et al., 2021). People over 60 years of age are most likely to suffer from  
269 different cardiovascular, central nervous system, respiratory, renal, and carcinogenic diseases  
270 (Nurchis et al., 2020). The present data also revealed that there was no major increase in DALYs  
271 for people aged 70 and above in comparison with the 60–65-year group. The life expectancy in  
272 Saudi Arabia is reported to be 75.13 years (Jo et al., 2020) and the data from this study suggests  
273 that there was no major loss in terms of YLL and YLD in this population group (Table-1).

274 Further, the cumulative DALYs/1,00,000 was found to be 87.50. The relative risk analysis due to  
275 COVID-19 indicated that case-fatality ratio and risk outcome increased according to the age of  
276 the population. A significant increase in RR values ( $RR = 1.55$ ,  $P = 0.037$ ) was observed from 40  
277 – 49 years of aged groups along with rise in CFR (0.92). The highest CFR and RR values were  
278 found for the people above 70 years old ( $CFR = 3.02$ ,  $RR = 2.84$ ,  $P = 0.006$ ) (Table-2). These  
279 values indicated similarity with previous study, where population with age 0 – 34 years had  
280 lower risk, but the risk increased after 35 years age (24). The DALY values when compared to

281 the previous studies suggested that the health care facilities offered to the COVID-19 patients  
282 have influenced positively in minimizing both the mortality and complications. The data when  
283 compared falls between 59 (Finland) and 116 (Denmark), reported to have managed well in  
284 controlling the COVID-19 pandemic (Naumann et al., 2020).

285 The mortality rate due COVID-19 was found to be 1.566% (Figure-1). This rate was found to be  
286 within the range (1–2%) of the well-managed countries and significantly lower than the global  
287 average fatality rate ( $\approx 3$ ). According to WHO, the infection due to COVID-19 cause mild  
288 symptoms in most people, however, complications and deaths were common in patients who are  
289 aged and sufferers of chronic diseases. Accumulated data from the MoH resources suggests that  
290 46% of Saudi Arabia's population suffers from cardiovascular disease. Incidences of these  
291 diseases were found to be more common in urban areas (Hussein and Ismail. 2017) and so the  
292 mortality rate was found to be high in major cities of Saudi Arabia (Figure-1). Obesity, diabetes,  
293 and hypertension was found to be frequent disorder amongst the patients diagnosed with  
294 metabolic diseases including the young population (Caussy et al., 2020). Obesity in the previous  
295 studies has been considered an important risk factor for severity due to COVID-19 (Sattar et al.,  
296 2020). A meta-analysis of COVID-19 patients indicated a strong relation between obesity and  
297 ICU admission after infection with COVID-19 (Yang et al., 2021). These studies indicated that  
298 obesity increases the chances of other diseases such as diabetes mellitus, renal insufficiency, and  
299 cancer, thus complicating the COVID-19 infection (Caussy et al., 2020; Sattar et al., 2020; Yang  
300 et al., 2021).

301 In hypertensive patients, the rennin-angiotensin system is reported to be in a hyperactive state  
302 and the SARS-CoV-2 has special affinity to angiotensin converting enzyme-2 (ACE-2). The  
303 virus uses them for entering the host and during COVID-19, the expression of ACE-2 was also  
304 found to be enhanced (Fang et al., 2020). In addition, the binding of SARS-CoV-2 to ACE-2  
305 reported to cause several alterations in the post-receptor signalling pathways that ultimately lead  
306 to vasoconstriction, pro-inflammatory response, endothelial dysfunction, and pro-thrombotic  
307 processes (Zhang et al., 2020). The likelihood of other co-morbidities in hypertensive patients  
308 reported to aggravates the complications of COVID-19 (Fang et al., 2020). Apart from these, the  
309 prevalence of cancer (10%), diabetes mellitus (5%) and respiratory diseases (3%) were also  
310 reported in Saudi population (Hussein and Ismail, 2017). The implication of these diseases has

311 been reported in the COVID-19 induced complications by several mechanism including altered  
312 immunological reactions (Fang et al., 2020).  
313 The incidences of these complications were reported to get enhanced according to the age of  
314 population (Hussein and Ismail, 2017). This correlation between age and increased mortality rate  
315 can be observed in the table 3. The data from this analysis indicated that correlation coefficient  
316 between age and mortality due to COVID-19 increased significantly ( $P<0.05$ ) from 40 years  
317 onwards and a strong correlation ( $r = 0.72$ ) can be observed in population of age above 60 years.  
318 The available data suggested that healthcare facilities in Saudi Arabia follow the standard  
319 updated guidelines of WHO while treating the COVID-19 patients. All the regions of the country  
320 have designated hospital to manage the complications of COVID-19. Besides, the COVID-19  
321 vaccination program was reported to have covered more than 70% of population, achieving the  
322 herd immunity (<https://covid19.moh.gov.sa>). The proactive, preventive and established  
323 therapeutic interventions implemented by healthcare providers could be linked to the  
324 management of current pandemic situation in Saudi Arabia. More research in this direction  
325 involving a greater number of patients might provide clarity on the actual burden of COVID-19  
326 in the country.  
327 Although we used a representative sample size to examine the COVID-19 burden in the Saudi  
328 Arabian population, we advise caution in generalizing this information without further validation  
329 in a larger sample size.

330

## 331 5. CONCLUSION

332 According to the findings of this study, the infection rate and COVID-19 death rates in Saudi  
333 Arabia are 1.54 % and 1.59 %, respectively. These figures indicated that the current impact of  
334 infection was within the range (1–2%) observed in nations that successfully handled the  
335 epidemic. An investigation of 2988 patients' disability adjusted lost years (DALYs) revealed that  
336 the values increased in those over 40. Further, persons over the age of 60 had a greater loss of  
337 life expectancy, and relative risk measurement demonstrated that this group of people was at a  
338 higher risk of mortality due to COVID-19. The burden of COVID-19 appears to have grown in  
339 adults over the age of 60, most likely due to the existence of other co-morbidities.

340

## 341 Acknowledgements

342 The authors are thankful to AlMaarefa University for providing support to do this research.

343

#### 344 REFERENCES

345

- 346 1. Alahmadi M, Atkinson PM. Three-fold urban expansion in Saudi Arabia from 1992 to 2013  
347 observed using calibrated DMSP-OLS night-time lights imagery. *Remote Sens.* 2019, 11,  
348 2266.
- 349 2. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of  
350 COVID-19. *Nature* 2021; 594: 259-264.
- 351 3. Alharbi MM, Rabbani SI, Asdaq SMB, Alamri AS, Alsanief WF. Infection Spread, Recovery,  
352 and Fatality from Coronavirus in Different Provinces of Saudi Arabia. *Healthcare.* 2021; 9:  
353 931-43.
- 354 4. Alkhowailed M, Shariq A, Alqossayir F, Alzahrani OA, Rasheed Z, Aladulmomem W. Impact  
355 of meteorological parameters on COVID-19 pandemic: A comprehensive study from Saudi  
356 Arabia. *Informatics in Medicine Unlocked.* 2020;20:100418.
- 357 5. Al-Tawfiq JA, Memish ZA. COVID-19 in the Eastern Mediterranean Region and Saudi  
358 Arabia: prevention and therapeutic strategies. *Int J Antimicrob Agents* 2020: 105968; 22-9.
- 359 6. Al-Zalfawi SM, Rabbani SI, Asdaq SMB, Alamri AS, Alsanief WF, Alhomrani M, Mohzari Y,  
360 Alrashed AA, AlRifdah AH, Almagrabe T. Public Knowledge, Attitude, and Perception  
361 Towards COVID-19 Vaccination in Saudi Arabia. *Int. J. Environ. Res. Public Health.* 2021;  
362 18: 10081.
- 363 7. Asharaf A, Alshekteria AA. Population and health in the eastern Mediterranean: A preliminary  
364 examination. *Middle East Journal of Age and Ageing.* 2008;5:26 – 39.
- 365 8. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality  
366 following COVID-19 infection. *Lancet Infect Dis* 2020; 20: 773.
- 367 9. Bonaccorsi G, Pierri F, Cinelli M, Flori A, Galeazzi A, Porcelli F, et al. Economic and social  
368 consequences of human mobility restrictions under COVID-19. *Proc Natl Acad Sci U S A.*  
369 2020; 117: 15530–15535.
- 370 10. Caussy C, Wallet F, Laville M, Disse E. Obesity is associated with severe forms of COVID-  
371 19. *Obesity (Silver Spring).* 2020;28(7):1175.

- 372 11. COVID-19 infection rate in Saudi Arabia, 2021. Available from:  
373 <https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/covid19.aspx>.  
374 [Accessed on 15th october, 2021]
- 375 12. COVID-19 vaccination update in Saudi Arabia. Available from; <https://covid19.moh.gov.sa>  
376 [Accessed on 18<sup>th</sup> October, 2021).
- 377 13. Deb P, Furceri D, Ostry JD, Tawk N. The economic effects of COVID-19 containment  
378 measures. Covid Econ Vetted Real-Time Pap. 2020; 24: 32–35.
- 379 14. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at  
380 increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
- 381 15. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P. Disease burden of the most  
382 commonly detected respiratory viruses in hospitalized patients calculated using the disability  
383 adjusted life year (DALY) model. J Clin Virol Off Publ Pan Am Soc Clin Virol 2011; 52: 215-  
384 221.
- 385 16. Gianino MM, Savatteri A, Politano G, Nurchis MC, Pascucci D, Damiani G. Burden of  
386 COVID-19: Disability-Adjusted Life Years (DALYs) across 16 European countries. Eur Rev  
387 Med Pharmacol Sci. 2021 Sep;25(17):5529-5541.
- 388 17. Hussein S, Ismail M. Ageing and elderly care in the arab region: policy challenges and  
389 opportunities. Ageing Int 2017; 42: 274–89.
- 390 18. Jo MW, Go DS, Kim R, Lee SW, Ock M, Kim YE, Oh IH, Yoon SJ, Park H. The Burden of  
391 Disease due to COVID-19 in Korea Using Disability-Adjusted Life Years. J Korean Med Sci  
392 2020; 35: 199.
- 393 19. Mathers CD, Salomon JA, Ezzati M, Begg S, Hoorn SV, Lopez AD. Sensitivity and  
394 Uncertainty Analyses for Burden of Disease and Risk Factor Estimates. In: Lopez AD, Mathers  
395 CD, Ezzati M, Jamison DT, Murray CJL, eds. ; 2006, Chapter 5. Available from:  
396 <https://www.ncbi.nlm.nih.gov/books/NBK11802/> Co-published by Oxford University Press,  
397 New York.
- 398 20. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life  
399 years. Bull World Health Organ 1994; 72: 429-445.
- 400 21. Naumann E, Möhring K, Reifenscheid M, Wenz A, Rettig T, Lehrer R, Krieger U, Juhl S,  
401 Friedel S, Fikel M, Cornesse C, Blom AG. COVID-19 policies in Germany and their social,  
402 political, and psychological consequences. Eur Policy Anal 2020; 6: 191-202.

- 403 22. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, Specchia ML,  
404 Laurenti P, Damiani G. Impact of the Burden of COVID-19 in Italy: Results of Disability-  
405 Adjusted Life Years (DALYs) and Productivity Loss. *Int J Environ Res Public Health* 2020;  
406 17: 4233.
- 407 23. Onder G, Rezza G, Brusaferro S. Case-Fatality ratio and characteristic of patients dying in  
408 relation to Covid-19 in Italy. *JAMA*. 2020, 323, 1775–1776.
- 409 24. Ritchie H, Roser M, Ortiz-Ospina E, Hasell J. Excess mortality from the Coronavirus pandemic  
410 (COVID-19). In: *Our World in Data* [Internet]. 2020. Available from;  
411 <https://ourworldindata.org/excess-mortality-covid>. [Accessed on 12<sup>th</sup> October, 2021].
- 412 25. Rothan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-  
413 19) outbreak. *Journal of Autoimmunity*. 2020;109:102433.
- 414 26. Sattar N, McInnes IB, McMurray JJV. Obesity a risk factor for severe COVID-19 infection:  
415 multiple potential mechanisms. *Circulation*. 2020;142(1):4–6.
- 416 27. World Health Organization WHO. Coronavirus disease (COVID-19) pandemic. Available,  
417 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. [Accessed in 10th  
418 October, 2021].
- 419 28. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis.  
420 *J Med Virol*. 2021;93(1):257-261.
- 421 29. Zhang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects Of ARBs And ACEIs on virus  
422 infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension:  
423 a single center retrospective study. *Hypertension*. 2020;76(1):51-58.
- 424 30. Zhou P. A pneumonia outbreak associated with a new coronavirus of probable bat origin.  
425 *Nature*. 2020; 579: 1–4.  
426

# Figure 1

Figure 1: positive test rate, infection rate and mortality rate




Figure 1: positive test rate, infection rate and mortality rate

## Figure 2

Figure 2: Mortality records in different cities of Saudi Arabia




Figure 2: Mortality records in different cities of Saudi Arabia

**Table 1** (on next page)

Table-1: Disability adjusted life years (DALYs) due to COVID-19 in Saudi Arabia.

1

2 **Table-1: Disability adjusted life years (DALYs) due to COVID-19 in Saudi Arabia.**

Age group	YLL	YLD	DALYs	DALYs / 1,00,000
0-9 Yrs	181	95	276	0.77
10-19 Yrs	696	128	824	2.32
20-29 Yrs	876	565	1441	4.05
30-39 Yrs	1682	1028	2710	7.63
40-49 Yrs	2167	1768	3935	11.08
50-59 Yrs	2904	2373	5277	14.86
60-69 Yrs	4194	3269	7463	21.02
Above 70 Yrs	5018	4119	9137	25.73

3 **Note:** YLL – Years of life lost, YLD – Years lost due to disability

4

**Table 2** (on next page)

Table-2: Relative risk (RR) of mortality due to COVID-19 in Saudi Arabia

1 **Table-2: Relative risk (RR) of mortality due to COVID-19 in Saudi Arabia.**

Age group	CFR	Lower 95% CI	Upper 95% CI	RR	Risk outcome	<i>p</i> -value
0-9 Yrs	0.00	0.125	0.198	0.05	- 95%	0.351
10-19 Yrs	0.01	0.204	0.369	0.12	- 88%	0.690
20-29 Yrs	0.12	- 0.988	0.108	0.61	- 39%	0.298
30-39 Yrs	0.29	0.074	0.158	1.02	2%	0.086
40-49 Yrs	0.92	- 0.257	- 0.169	1.55*	55%	0.037
50-59 Yrs	1.26	0.369	0.485	1.78*	78%	0.043
60-69 Yrs	2.11	0.128	0.315	2.32**	132%	0.008
Above 70 Yrs	3.02	- 0.159	0.088	2.84**	184%	0.006

2 **Note:** Relative risk analysis from COVID-19. \* $p < 0.05$ , \*\* $p < 0.01$  compared between groups.

3

**Table 3** (on next page)

Table-3: Summary of Pearson correlation analysis between age and mortality due to COVID-19.

1 **Table-3: Summary of Pearson correlation analysis between age and mortality due to**  
 2 **COVID-19.**

Age group	Correlation coefficient (r)	Lower 95% CI	Upper 95% CI	Significance level of two-tailed 't' test
0-9 Yrs	- 0.24	0.152	0.179	0.622
10-19 Yrs	0.16	0.246	0.392	0.981
20-29 Yrs	0.31	- 0.236	0.096	0.265
30-39 Yrs	0.38	0.095	0.108	0.723
40-49 Yrs	0.56*	0.221	0.462	0.032
50-59 Yrs	0.64*	0.146	0.197	0.044
60-69 Yrs	0.72**	- 0.016	0.042	0.006
Above 70 Yrs	0.78**	0.104	0.211	0.007

3 **Note:** Pearson correlation analysis. \* $p < 0.05$ , \*\* $p < 0.01$  compared between groups.

4